X
Translate:
Media Inquiries?
Please call

04/20/20

RUTGERS, UNIVERSITY HOSPITAL LEAD WAY IN TREATING COVID-19 WITH CONVALESCENT PLASMA FROM RECOVERED PATIENTS

Researchers, doctors call for more blood donations from former patients to help treat critically ill

Rutgers physicians and University Hospital are leading the way in using blood plasma from patients who recovered from COVID-19 to treat new patients who are severely ill with COVID-19 infections. The clinicians and hospital are calling for more blood donations from those who have survived the deadly infection.

Although COVID-19 infections and fatalities continue to increase in New Jersey and across the United States, more than 50,000 people have recovered from the novel virus. Their blood plasma
contains antibodies that may help critically ill patients fight, and perhaps conquer, the virus.

Last Friday, Rutgers practitioners at University Hospital received the first FDA approval for this treatment in New Jersey, and have thus far treated 17 patients with convalescent plasma. FDA
approval is pending for the use of this treatment for additional patients.

The effectiveness of this treatment is not yet known, though similar treatment has been studied for Ebola and the MERS virus. Practitioners and researchers will monitor and investigate the progress of COVID-19 patients who receive this treatment.

“The use of convalescent plasma – blood plasma from individuals who have recovered from COVID-19 – presents real hope for saving lives,” said Marc Klapholz, Chair of the Department of Medicine at Rutgers New Jersey Medical School and University Hospital, and the Principal Investigator for the use of Convalescent COVID-19 plasma.

“In our battle against the COVID-19 virus, we are excited to be trialing this potential life-saving therapy in partnership with Rutgers New Jersey Medical School. This treatment plan has been
used for more than 100 years to address disease outbreaks for other conditions, and we’re optimistic that it will save lives,” said Shereef Elnahal, President and CEO of University Hospital.

People interested in donating plasma must have had a confirmed positive test for COVID-19 from a lab or health facility and be eligible to donate blood. They can reach the Rutgers and
University Hospital COVID-19 Treatment Group at 973-972-5474 or via email at covidplasma@uhnj.org.

Other Recent News Stories
07/01/23

University Hospital Joins Vizient/AACN Nurse Residency Program™

Newark, New Jersey, July 2023 – University Hospital today announced the implementation of a Nurse Residency program based on the Vizient and American Association of Colleges of Nursing (Vizient/AACN) Nurse Residency Program™. The program is designed to ease the transition of newly graduated nurses from the classroom setting to the clinical practice environment to promote …

University Hospital Joins Vizient/AACN Nurse Residency Program™ Read More »

More
08/28/23

UNIVERSITY HOSPITAL WELCOMES SENIOR VICE PRESIDENT, CONSTRUCTION AND REAL ESTATE

NEWARK, NJ — University Hospital (UH) has selected Jennifer Denault as its new Senior Vice President, Construction and Real Estate. She will lead the Hospital’s highly anticipated campus project, oversee the current maintenance and facilities support services, and manage the existing groups that operate University Hospital’s facilities. Jennifer joins University Hospital at a crucial time …

UNIVERSITY HOSPITAL WELCOMES SENIOR VICE PRESIDENT, CONSTRUCTION AND REAL ESTATE Read More »

More
09/21/23

UNIVERSITY HOSPITAL RATED ONE OF AMERICA’S BEST EMPLOYERS IN STATE BY FORBES FOR THIRD CONSECUTIVE YEAR

Employee Recognition Signals Hospital’s Continued Track Record of Success and Achievement NEWARK, NJ — For the third consecutive year, University Hospital (UH), one of New Jersey’s original academic medical centers and the only NJ-certified Level 1 Trauma Center in Northern New Jersey as well as the principal affiliate of the Rutgers New Jersey Medical School, …

UNIVERSITY HOSPITAL RATED ONE OF AMERICA’S BEST EMPLOYERS IN STATE BY FORBES FOR THIRD CONSECUTIVE YEAR Read More »

More
Scroll to Top